Open AccessNew approaches in palliative systemic therapy of anal squamous cell carcinoma
Author(s) -
Radka Lohynská,
Zden̆ka Pechačová
Publication year - 2022
Publication title -
klinická onkologie
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.204
H-Index - 13
eISSN - 1802-5307
pISSN - 0862-495X
DOI - 10.48095/ccko2022190
Subject(s) - medicine , docetaxel , oncology , regimen , palliative care , chemotherapy , carboplatin , immunotherapy , systemic therapy , cisplatin , cancer , breast cancer , nursing
Metastatic and locally recurrent inoperable anal squamous cell carcinoma (ASCC) belong to rare tumours - ASCC accounts for about 2% of gastrointestinal tumours. Synchronous metastatic involvement is usually confirmed in approximately 15% of patients and about 20 % of patients develop relapse in the form of distant metastases after curative treatment. The current standard palliative systemic treatment is a PF regimen composed of 5-fluorouracil (5-FU) with cisplatin (cDDP) or a combination of carboplatin with paclitaxel.